Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment with similar efficacy across conventional LBCL subtypes. Toward patient stratification, we assessed whether tumor immune co...

Descripción completa

Detalles Bibliográficos
Autores principales: Scholler, Nathalie, Perbost, Regis, Locke, Frederick L., Jain, Michael D., Turcan, Sarah, Danan, Corinne, Chang, Edmund C., Neelapu, Sattva S., Miklos, David B., Jacobson, Caron A., Lekakis, Lazaros J., Lin, Yi, Ghobadi, Armin, Kim, Jenny J., Chou, Justin, Plaks, Vicki, Wang, Zixing, Xue, Allen, Mattie, Mike, Rossi, John M., Bot, Adrian, Galon, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499856/
https://www.ncbi.nlm.nih.gov/pubmed/36038629
http://dx.doi.org/10.1038/s41591-022-01916-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499856/
https://www.ncbi.nlm.nih.gov/pubmed/36038629
http://dx.doi.org/10.1038/s41591-022-01916-x

Ejemplares similares